San Diego, USA
Shanghai, China
March 23, 2023

 

ABM Therapeutics, Inc, a clinical-stage biopharmaceutical company with a focus on treating brain cancers and cancer metastases today announced 4 cancer research posters will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place in Orlando, Florida, April 14-19.

 

Poser #4177, in the session of Novel Antitumor Agents 1 (Abstract #476)

Title: ABM-1310 has significant improved blood-brain barrier (BBB) penetration and intracranial tumor growth inhibition compared to FDA approved BRAF inhibitors
Compared with the approved BRAF V600 inhibitors, ABM-1310 has significantly improved blood-brain barrier permeability, can effectively inhibit the growth of intracranial tumors, and prolong the survival of intracranial tumor-bearing animals. The clinical research of ABM-1310 is ongoing in multiple clinic centers in the United States and China. We hope ABM-1310 will bring new treatment options to patients with brain metastases or primary brain tumors.

 

Poster #4038, in the session of Novel Antitumor Agents 1 (Abstract #475)
Title：Preclinical development of ABM-168, a novel MEK Inhibitor to treat cancer with brain tumors
This poster shows the results of multiple preclinical experiments on small-molecule allosteric MEK inhibitor, ABM-168, developed by ABM Therapeutics. Compared to FDA-approved small molecules MEK inhibitors, ABM-168 has a smaller molecular weight and significantly improved blood-brain barrier permeability. The IND of ABM-168 was approved by the FDA in October 2022. Phase I clinical trial is ongoing in multiple clinic centers in the United States.

 

Poster #6238， in the session of DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents (Abstract #6238)
Title：ABM-2752, a potent and selective HPK1 inhibitor with excellent efficacies as a single agent or in combination with a PD-1 antibody
This poster shows the results of multiple preclinical experiments on a novel small molecule HPK1 inhibitor, ABM-2752, developed by ABM Therapeutics. ABM-2752 shown good efficacies in multiple in vivo models. In ADME and PK studies, ABM2752 also showed good drug-like properties. The project is currently in process of the IND-enabling studies.

 

Poster #5982, in the session of Cyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors (Abstract #1080)
Title：A potent and selective CDK8 inhibitor ABM-3249 with excellent efficacies in multiple in vivo cancer models.
This poster shows the results of multiple preclinical experiments of small molecule CDK8 inhibitor ABM-3249，which was developed by ABM Therapeutics. ABM-3249 potently inhibited the enzymatic activity of CDK8 (IC50=1.3nM), it also significantly inhibited the phosphorylation of downstream molecule STAT1. In the MC38 syngeneic model, ABM-3249 single drug effectively inhibited tumor growth, and shown a synergic tumor inhibitory effect when combined with a PD-1 antibody. In preliminary tolerance studies, ABM-3249 also showed a good safety window.

 

About ABM Therapeutics
ABM Therapeutics, a clinical-stage biopharmaceutical company with a mission to focus on the small molecule research and development of novel drugs for the treatment of cancer, and on brain cancer and cancer metastases. ABM has been building its broad and robust proprietary pipeline to construct a brain medicine R&D platform through collaboration with CROs. ABM’s pipeline includes several programs in various stages of discovery and development, most of which have improved brain permeability to address the unmet needs of treating cancers and metastases in the brain.